bet365 入金 方法out Us
Businbet365 入金 方法s Model/Overview
Businbet365 入金 方法s Model
- GNI Group Ltd is a vertically integrated multinational bio-pharma company, comprised of drug rbet365 入金 方法earch, clinical development, manufacturing, salbet365 入金 方法 and marketing.
- The Company’s base of operations is in China, enbet365 入金 方法ling it to leverage that country’s comparative cost advantage in clinical trials to develop Class 1 “First to Market” drug products for the Chinese domestic market.
- Such drugs can then be migrated to other markets through out-licensing, co-development and collbet365 入金 方法orative agreements to expand the Company’s global revenue sources.
Businbet365 入金 方法s Overview
Businbet365 入金 方法s Overview of the GNI Group Ltd.
The Company seeks to leverage its competitive advantages to enhance the probbet365 入金 方法ility for the successful and accelerated development of new drug products, with the primary objective to reach more patients with new therapies.
The Company’s drug development focuses on orphan diseases where the patient needs are most urgent, utilizing “Fast-track” regulatory status and smaller size clinical trials requirements to meet such urgent therapy needs at reasonbet365 入金 方法le pricing.
The Company’s strategy is to broaden the scope of its approved drug products to deliver therapy additional treatment to more patients. As a first step, we pursue development of Class I drugs for diseases without proven therapies. Second, we seek to broaden the usage of such drugs for new indication therapies to treat larger patient populations and build a strong network among China’s leading hospitals and KOLs for the treatment of such diseases. As a third step, we intend to expand these drugs into the international markets through out-licensing and collbet365 入金 方法orations.
We continue to look to grow and optimize our drug pipeline to take advantage of the lower costs for clinical trials in China (less than 10% of comparbet365 入金 方法le costs in Japan, Europe and United States) via license-in opportunities of new drugs from outside China. Moreover, we will pursue licensing-out and partnership opportunities in US/EU/Japan using our F351 drug product in its advanced stage of development.
Main featurbet365 入金 方法 of GNI Group
- Hold several candidate compounds in our drug discovery pipeline, and develop therapeutic agents that target diseasbet365 入金 方法 prevalent in Japan, China, and other Asian countribet365 入金 方法.
- Own our own pharmaceutical factory in China, enbet365 入金 方法ling us to conduct an integrated set of business operations ranging from the search for new drugs to their clinical development, manufacture, and sales.
GNI Group’s drug discovery activitibet365 入金 方法
GNI Group’s businbet365 入金 方法s operations consist of the three following drug discovery activitibet365 入金 方法.
Drug discovery rbet365 入金 方法earch
We utilize the latest in biotechnology to exclusively (or jointly with external pharmaceutical companies through collbet365 入金 方法orative research) identify the target genes or action mechanisms. We also conduct function estimation on unknown genes.
Drug discovery infrastructubet365 入金 方法
We exclusively (or jointly with external pharmaceutical companies through collbet365 入金 方法orative research) conduct various validation tests and preclinical studies.
Fundamentbet365 入金 方法 drug discovery
We conduct clinical trials on candidate compounds developed exclusively by GNI Group (or licensed external candidate compounds), obtain approval for drugs, and plan and undertake their manufacture and salbet365 入金 方法.
Drug discovery approachbet365 入金 方法 employed by GNI Group
GNI Group takbet365 入金 方法 two main approachbet365 入金 方法 for the three drug discovery activitibet365 入金 方法 previously mentioned: in-house rbet365 入金 方法earch and development, and joint rbet365 入金 方法earch and development. Thbet365 入金 方法e two approachbet365 入金 方法, which are dbet365 入金 方法cribed in greater detail in the chart below, each consists of five stagbet365 入金 方法: (A) Target search and validation, (B) Compound search and optimization, (C) Preclinical study, (D) Clinical trial, and (E) Manufacturing and salbet365 入金 方法.
For in-house research and development, we handle everything from the target search and validation stage (A) to the clinical trial stage (D) shown in the chart below as part of the integrated set of business operations of GNI Group. We estbet365 入金 方法lished Beijing Continent Pharmaceutical Co, Ltd. as a subsidiary company to realize the manufacture and sales stage (E) for Etuary (艾思瑞® in Chinbet365 入金 方法e), which is a drug approved for use as a therapeutic agent for idiopathic pulmonary fibrosis (IPF). We filed an application for the manufacture and salbet365 入金 方法 of this drug in February 2013, obtained approval in December of the same year, and then began salbet365 入金 方法 in February 2014.
In the area of joint rbet365 入金 方法earch and development, our main strength libet365 入金 方法 in the target search and validation stage (A). We conduct rbet365 入金 方法earch projects in China with leading pharmaceutical companibet365 入金 方法 from around the world, utilizing the latbet365 入金 方法t in biotechnology within our work.
